On July 6, 2021 Genpre reported that it’s lead drug candidate, REQORSA Immunogene Therapy that uses our proprietary, non-viral ONCOPREX Nanoparticle Delivery System was highlighted in a Key Opinion Leader event hosted by Alliance Global Partners (AGP) for their institutional customers (Press release, Genprex, JUL 6, 2021, View Source [SID1234584654]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event, titled, "Advances in Gene Therapy for Oncology: New Opportunities with REQORSA (TUSC2)," was moderated by James Molloy, Managing Director, Equity Research at AGP and featured discussions with experts Andrew Becker, M.D., Ph.D. and COL (ret) George Peoples, M.D., FACS.
The presentation gave an overview of REQORSA and ONCOPREX, including discussions suggesting that REQORSA could be the first systemic gene therapy used for cancer in humans. It also featured the large markets that REQORSA is addressing, as well as REQORSA and ONCOPREX’s potential to address a range of cancers.
The discussion also reviewed highlights from Genprex’s two previous clinical trials, ONC-001, a REQORSA monotherapy clinical trial; and ONC-002, a combination of REQORSA and Roche’s Tarceva in NSCLC.
The KOLs also discussed the importance of the positive preclinical data presented in April at the 2021 American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting that supported the use of REQORSA in combination with immunotherapies and with targeted therapies for the treatment of NSCLC.
On the Company’s Acclaim-1 and upcoming Acclaim-2 clinical trials:
"What I like about these trial designs is the potential to get added value and added time for patients out of Keytruda and Tagrisso, in order to delay the time before the patient has to begin a more toxic chemotherapy regimen," said Dr. Becker. "The ability to continue on a PD-1 inhibitor or a targeted therapy longer, in patients that we know are tolerating it, is a benefit to the patient because it not only extends life, but it extends quality of life."
On the positive preclinical data presented by our academic collaborators at the AACR (Free AACR Whitepaper) annual meeting supporting REQORSA:
"These AACR (Free AACR Whitepaper) studies are incredibly important because they are addressing the use of REQORSA in combination with what is the most current way we treat NSCLC patients clinically," said Dr. Peoples. "What you will see with the AACR (Free AACR Whitepaper) studies, is that Genprex is encompassing all of the patients in the first-line therapy setting, whether they have EGFR mutations and fall into the targeted therapy category, or if they are PD-L1 positive patients who will get pembrolizumab or a pembrolizumab combination with platinum chemotherapy. The data covers the majority of the first-line patients in these two AACR (Free AACR Whitepaper) presentations."
Learn more about the KOLs by reading Dr. Becker’s and Dr. Peoples’ bios. To watch the presentation in its entirety, a replay of the event can be found on the Genprex website. Since the KOL event recording on April 27, 2021, Genprex has initiated its Acclaim-1 clinical trial and has updated the Acclaim-2 protocol to include all late-stage NSCLC patients who have progressed after treatment with Keytruda, regardless of PD-L1 expression.